Compare Mesoblast Limited (MESO) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tyson Foods, Inc. — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Tyson Foods, Inc. trades at $58.17 (market cap $20.42B). The key difference: Tyson Foods, Inc. is far larger — about 9.4× Mesoblast Limited's market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TSN | |
|---|---|---|
Market Cap | $2.17B | $20.42B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $68.75 |
52-Week Low | $12.88 | $50.72 |
Enterprise Value | $2.17B | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Tyson Foods (TSN) trades at $58.245, up 0.82% today, with a bearish technical signal but mixed earnings history. The company reported Q1 2026 EPS of $0.87, beating estimates, but faces margin pressures with a net income margin of 0.81%. Recent news highlights strategic product launches and executive appointments, while cash flow trends show operational strength but negative net cash flow in 2025.
Outlook is cautiously optimistic with a consensus price target of $68.80, implying 18% upside, supported by 50% analyst buy ratings. Risks include volatile protein markets and debt levels, but long-term growth in prepared foods and dividend stability offer value. Investors should weigh near-term margin challenges against strategic initiatives and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
